Alto Neuroscience, Inc. announced today that it has entered into an asset purchase agreement with Chase Therapeutics Corporation to acquire a portfolio of dopamine agonist drug combinations. This acquisition includes ALTO-207, formerly CTC-501, for treatment-resistant depression (TRD), and ALTO-208, formerly CTC-413, for Parkinson's disease.
Under the terms of the agreement, Alto paid an upfront payment of $1.75 million, with Chase Therapeutics eligible for up to an aggregate of $71.5 million in future milestone payments, of which $41 million are tied to commercial success. ALTO-207 is a fixed-dose combination of pramipexole and ondansetron, designed to enable rapid titration and higher dosing by mitigating dose-limiting adverse events.
ALTO-207 previously met primary and secondary endpoints in a completed Phase 2a study in MDD, demonstrating significantly greater improvements on the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to placebo, with a Cohen’s d of 1.1 at Week 8. Alto expects to initiate a Phase 2b trial for ALTO-207 in TRD, designed to be a potentially pivotal study, by mid-2026 and report topline data in 2027.
This strategic transaction expands Alto's pipeline with a major late-stage clinical readout without altering its current cash runway guidance, which is expected to fund planned operations into 2028. The acquisition leverages Alto's proprietary insights on dopamine biomarkers in depression to advance these differentiated product candidates.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.